At a glance
- Originator Kyorin Pharmaceutical
- Class
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia
Most Recent Events
- 07 Nov 2006 Discontinued - Preclinical for Cerebral ischaemia in Japan (unspecified route)
- 26 Apr 2002 Preclinical trials in Cerebral ischaemia in Japan (unspecified route)